December 2020 in “Innovation in aging” This study suggests that inhibiting PKC, similar to rapamycin treatment, can extend lifespan and reduce neurological symptoms and inflammation in mice with mitochondrial dysfunction, potentially involving the mTORC2 pathway.
October 2024 in “Our Dermatology Online” This study highlights a close link between metabolic syndrome, characterized by conditions like obesity and hypertension, and various inflammatory skin diseases, suggesting that mitochondrial dysfunction plays a key role in their pathogenesis and could be a target for new therapies.
26 citations
,
December 2020 in “Nature metabolism” Martin-Perez et al. show that rapamycin's beneficial effects in a mouse model of Leigh syndrome are linked to the downregulation of protein kinase C.
January 2026 in “Frontiers in Pharmacology” This study suggests that cedrol may improve mitochondrial function, gut microbiota, and intestinal barrier integrity, indicating its potential value in treating inflammatory bowel disease.
August 2026 in “BMC Nephrology” In this study, a young Chinese male with a specific mitochondrial mutation was reported to have proteinuria and renal dysfunction, with stable kidney function after treatment over 23 months.
